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THE local production of tumour necrosis factor-0t (TNF0t)
was evaluated in the cerebrospinal fluid (CSF) from ten
patients with tuberculous meningitis (TBM). The degree
of intrathecal immune activation was also studied by
assessing the CSF levels of 2-microglobulin (2-M) and
adenosine deaminase activity (ADA). Results indicate that
elevated CSF concentrations of TNF0t, 12-M and ADA
were found in all TBM patients. Moreover, TNF0t is
produced and selectively concentrated for a long period of
time, while 2-M and ADA values progressively decline
during the course of TBM. Our findings suggest that in
TBM patients, after an early activation of immune cells,
there is an enhanced and continuous production of TNF0t
at the site of infection.
Key words: Adenosine deaminase, fl2-microglobulin, Cere-
brospinal fluid, Immune activation, Tuberculous meningitis,
Tumour necrosis factor-cz
Tumour necrosis factor-=
production and immune cell
activation in tuberculous
meningitis
C. M. Mastroianni,cA F. Paoletti, C. Valenti,
A. P. Massetti, V. Vullo and S. Delia
Institute of Infectious Diseases, University ’La
Sapienza’, Policlinico Umberto I, Viale Regina
Elena 331, 00161 Rome, Italy
CA Corresponding Author
Introduction
Tumour necrosis factor-o (TNFo0 is a cytokine
mainly released by cells of the monocyte-
macrophage lineage in response to lipopolysacchar-
ide (LPS) and other immune and inflammatory
stimuli. It has been recognized as a primary
mediator in the pathogenesis of infection, injury
and inflammation and in the beneficial processes of
host response. In particular, TNFe is an important
macrophage-activating factor for antibacterial re-
sistance against infections caused by facultative
intracellular organisms, such as mycobacteria.
2
In experimental models it has been reported that
TNF enhances macrophage phagocitic capacity
and mycobacterial killing by human macrophages.
In addition, recent lines of evidence indicated that
TNF is synthesized in large amounts in pulmonary
tuberculosis and it is locally concentrated at the site
of disease activity.
4,s To date, little is known about
the intrathecal production of TNF during the
course of tuberculous meningitis (TBM).
6 There-
fore, it appears to be of interest to evaluate the local
production and release of TNFo in the cere-
brospinal fluid (CSF) of patients with TBM.
In the present study, TNFo concentrations were
measured in CSF specimens obtained from hospital
patients on admission and during the course of
TBM. In order to determine the extent to which
cell-mediated immunity is involved in the disease,
the CSF levels of two markers of immune
activation, such as fl2-microglobulin (/2-M) and
adenosine deaminase activity (ADA), were also
measured.
Materials and Methods
Patients: Ten patients with TBM (five males, five
females) admitted to the Institute of Infectious
Diseases of the University of Rome ’La Sapienza’,
were enrolled in this study. The mean age was 34.4
years (range, 12-55 years). TBM was diagnosed on
the basis of findings in the CSF. In six cases CSF
smears were positive by acid-fast staining and fluid
cultures grew Mycobacterium tuberculosis; in the
remaining patients, diagnosis was made by
compatible cytological and biochemical findings,
supported by clinical features and symptomatic
improvement with antituberculous therapy. All
patients were sero-negative for human immuno-
deficiency virus (HIV) and did not have other
disturbances of immunity.
A total of 66 CSF samples was collected from
TBM patients before starting treatment and
subsequently at various intervals of time during the
course of infection.
CSF specimens were also obtained from 15
patients with non-infectious neurological disorders,
including cerebrovascular disease, hydrocephalus,
encephalomyelitis and epilepsy.
CSF specimens, upon collection, were placed in
a refrigerated centrifuge (4C) and spun at
3 000 rpm for 10 min. Cell supernatants were stored
at -80C until use.
Assayfor TNF: TNF concentrations in CSF were
measured by a quantitative immunoenzymatic
sandwich assay (Quantikine, R&D Systems, Min-
neapolis, MN, USA). Samples and standards were
(C) 1994 Rapid Communications of Oxford Ltd Mediators of Inflammation. Vol 3. 1994 57C. M. Mastroianni et al.
incubated in anti-TNF monoclonal antibody-
coated polystyrene microtiter wells. A horseradish
peroxidase-conjugated anti-TNF0 polyclonal anti-
body was then added and allowed to bind theTNF
captured by the first antibody, completing the
sandwich. After washing, substrate solution was
added to the wells. The reaction was stopped by
addition of 2N HiSO4 and optical density (OD) at
492 nm was measured using an ELISA microreader.
To estimate the amount of TNFz in the CSF
samples we constructed a standard curve by using
concentrations of TNF ranging from 0 to
1000pg/ml. Unknown values of TNF in the
samples were determined by referring to the
standard curve and expressed as pg/ml. The
detection limit of the assay was 4.8 pg/ml.
Assay for fie-M: /2-M concentrations were assessed
by the IMx system (Abbott Laboratories, North
Chicago, IL, USA), according to the manufacturer’s
instructions. The IMx system is based on a rapid
microparticle enzyme immunoassay (MEIA), in
which submicron particles are coated with a mouse
monoclonal antibody specific for/2-M. The use of
microparticles increases the assay kinetics and
decreases the assay incubation. The sensitivity of
the IMx /2-M was calculated to be better than
5 tg/1. Normal/2-M values were considered equal
or less than 3 mg/1.
ADA activity measurement: ADA activity was mea-
sured in fresh CSF samples after centrifugation at
300 g for 10 min. ADA assay was performed at
37C by using the colorimetric method of Giusti,v
based on the determination of the amount of NH3
released in the reaction mixture. The enzymatic
activity was calculated by referring to a standard
curve of ammonium sulphate in buffer and was
expressed as IU/37C/1. Normal ADA values were
considered equal or less than 4 IU/1.
Statistical analysis: The Mann-Whitney U-test was
used for statistical analysis.
Results
CSF levels of TNF, /2-M and ADA were
measured in ten patients with TBM and in 15
control subjects with non-infectious CNS disorders.
Data are shown in Figure 1 and are expressed as
mean + SEM. TNF concentrations in TBM
patients (155_21.62pg/ml) were significantly
higher than those found in controls (5.69-+-0.77
pg/ml) (p < 0.0001). Similarly, TBM patients had
elevated CSF values of/32-M (8.69 ___
1.07 mg/1) and
ADA (10.83 _+ 1.61 IU/37C/1)in comparison with
those observed in the non-TBM cases (1.34 -t- 0.12
mg/1 and 1.02 0.16 IU/37C/1, respectively) (p <
0.0001 for both).
The kinetics of TNF0 and both j2-M and ADA
values during the course of TBM were illustrated
respectively in Figures 2 and 3.
In all patients CSF levels of TNF were low on
admission, then progressively increased and re-
mained detectable for a long period of time.
Antibiotic treatment did not appear to influence the
TNF levels. Similarly, there was no correlation
between the cytokine concentrations and the clinical
course of the disease.
On the contrary,/2-M and ADA values resulted
to be elevated on admission. Later, a progressive
decline was observed. Only two patients with
culture-proven TBM showed a further increase in
CSF/2-M and ADA values, despite the administra-
tion of antituberculous treatment. The peak of these
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FIG. 1. Levels of/t2-M, ADA and TNF in the CSF samples (n 66) from TBM patients compared with those (n 15) obtained in
controls with non-infectious neurological diseases. Data are expressed as the mean ___
SEM. Comparisons between groups are made by
non-parametric test (Mann-Whitney U-test) and differences in CSF levels of/Y2-M, ADA and TNF were statistically significant (p < 0.0001
for all).
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FIG. 2. Time course of TNF levels in sequential CSF samples from the ten TBM patients.
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FIG. 3. Time course of J2-M and ADA levels in sequential CSF samples
from the ten TBM patients.
immune activation markers was associated with the
development of complications (hydrocephalus,
hemiplegia) and an unfavourable clinical course of
meningitis.
Discussion
Cetl-mediated immunity plays an important role
in the control of infections by M. tuberculosis. It is
widely assumed that T-lymphocytes, through
lymphokine-mediated macrophage activation, are
the major immune cells involved both in the
pathogenesis and protective mechanisms in human
tuberculosis.1
5’0 In the case of TBM, it is conceivable that the
involvement of cellular immune system mainly
occurs in the central nervous system (CNS). In this
respect, the dosage in the CSF of two markers of
immune activation, such as fl2-M and ADA,
represents a useful tool to investigate the degree to
which cell-mediated immunity is stimulated in the
CNS. /2-M is a portion of the major histocompat-
ibility complex class I antigen (MHC-1) and is
expressed on the surface of lymphocytes and
macrophages. With regard to the adenosine
deaminase, the activity of this enzyme is increased
in lymphoid cells, especially during T-cell prolifera-
tion and differentiation.
Previous investigations have already demon-
$0 strated a close correlation between elevated CSF
ADA values and TBM,1’12 while an increase in the
CSF concentrations of/2-M has been reported only
in viral and pyogenic meningitis.
13 In the present
Mediators of Inflammation. Vol 3.1994 59C. M. Mastroianni et al.
study, both /2-M and ADA levels were found to
be elevated in the CSF of all TBM patients, thus
indicating a marked stimulation of immune system
within the CNS. The increased CSF levels of/2-M
were possibly a consequence of cell-mediated
cytotoxicity directed against macrophages infected
by M. tuberculosis. 14 The elevation of CSF ADA
values was most likely related to the local immune
response as the result of proliferating lymphocytes
in response to mycobacterial antigen.
Intrathecal immune activation appears to be also
associated with increased cytokine expression in the
CNS. Indeed, our results showed that TBM patients
had significantly higher CSF TNFo concentrations
than those found in control subjects with
non-infectious neurological diseases. The local
production of TNF is low in the initial phase of
TBM, while the peak in the CSF concentration was
obtained later. Moreover, the CSF levels of this
cytokine did not decrease during the course of the
disease, but they were elevated for a long time in
all patients, irrespective of the antibiotic therapy
and the clinical course ofTBM. This pattern is quite
different from that observed in the case of/2-M and
ADA, whose levels declined rapidly during the
course of the disease. Only two patients who
developed neurological complications showed a
further increase in the CSF/2-M andADA values.
Taken together, our findings suggest that a great
stimulation of immune T-cells primarily occurs in
the acute phase of TBM and may account for the
early increase in the CSF /2-M and ADA values.
On the contrary, the enhancement of cytokine
expression related to TNF production is a later
but more prolonged phenomenon. It is likely that
brain macrophages activated by T-cell-mediated
pathway are the source of TNFo in TBM patients.
This hypothesis is also supported by previous
investigations that have demonstrated that M.
tuberculosis cell wall components can trigger the
release of TNFo from human and murine
macrophages, as well as from pleural fluid
mononuclear cells of patients with pulmonary
tuberculosis. 5,15,16
In conclusion, our data provide direct evidence
that TNFo is produced and selectively concentrated
for a long period of time in the CSF from patients
with TBM. The chronic release of TNFo at the site
of the infection suggests that this cytokine may be
involved in the complex immunoregulatory mech-
anism that contributes to mycobacterial contain-
ment and elimination.
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